Retrospective, Non-Interventional, Multicenter Study on the Effectiveness and Safety of Intravesical Bacillus Calmette–Guerin in Patients with Non-Muscle-Invasive Bladder Cancer: Real-World Experience from Six Hospital Centers in Greece
Current Oncology · 2024
DOI: 10.3390/curroncol32010018 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Current Oncology, 2024. Verfasst von Panagiotis Angelopoulos und 23 weiteren Autor:innen. Beteiligte Einrichtung: 2nd Department of Urology, Sismanogleio Hospital, Medical School, National and Kapodistrian University of Athens, 15126 Athens, Greece. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, BCG Vaccine. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
While the clinical application of SII-ONCO-Bacillus Calmette–Guerin (BCG) for non-muscle-invasive bladder cancer (NMIBC) is well established in Greece, there is a lack of real-world data on its effectiveness and safety. This retrospective, observational, multicenter, chart-review study aims to provide real-life data on the effectiveness and safety of SII-ONCO-BCG in patients with intermediate- and high-risk NMIBC.
Methods
From January 2016 to December 2023, medical records from six hospital centers were reviewed for adult patients with histologically confirmed stage Ta or T1 NMIBC (with or without carcinoma in situ [CIS]) who received at least one maintenance course of SII-ONCO-BCG after induction. Tumor recurrence and progression were monitored at scheduled time intervals. Primary outcomes included recurrence-free survival (RFS) and progression-free survival (PFS), while adverse events (AEs) constituted secondary outcomes.
Results
A total of 162 patients receiving SII-ONCO-BCG were enrolled. Among all patients, 145 (89.5%) patients were men, 88 (54.3%) aged 70 years or older, 103 (63.6%) had T1, 43 (26.5%) Ta, and 21 (12.9%) concurrent CIS. The median follow-up duration was 28.9 months (range, 5–36) and the mean BCG intravesical instillation courses were 13.7 (range, 9–27). After 3-, 2-, and 1-year follow-up, RFS rates of 85.2% (95% CI, 79.7–90.7%), 85.8% (80.4–91.2%), and 87.0% (81.8–92.3%) were observed, respectively. The corresponding 3-, 2-, and 1-year PFS rates were 96.9% (94.2–99.6%), 96.9% (94.2–99.6%), and 97.5% (95.1–99.9%), respectively. During the whole follow-up period, 24 (14.8%) patients experienced at least one AE.
Conclusions
This real-world study demonstrates that SII-ONCO-BCG is an effective and safe treatment for patients with intermediate- and high-risk NMIBC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- 2nd Department of Urology, Sismanogleio Hospital, Medical School, National and Kapodistrian University of Athens, 15126 Athens, Greece.
- Department of Urology, General Hospital of Athens G. Gennimatas, 11527 Athens, Greece.
- 1st Department of Urology, "Laiko" Gen. Hospital, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.
- 2nd Urology Department of Medical School, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece.
- Health Through Evidence, 17456 Athens, Greece.
- Department of Accounting and Finance, School of Management, University of the Peloponnese, 24150 Kalamata, Greece.
ORCID-Profile: Lazaros Lazarou, Panagiotis Stamatakos, Napoleon Moulavasilis, Dimitrios Papanikolaou, George Mavridoglou, Konstantinos Skriapas, Dimitra Akrivou, George Gourzoulidis
Zitieren
APA
Angelopoulos, P., Markopoulos, T., Lazarou, L., Skolarikos, A., Stamatakos, P., Papadopoulos, G. I., Fragkoulis, C., Ntoumas, K., Moulavasilis, N., Levis, P., Papanikolaou, D., Sokolakis, I., Hatzimouratidis, K., Tzanetakos, C., Psarra, M., Mavridoglou, G., Skriapas, K., Akrivou, D., Karagiannis, D., …, & Mitropoulos, D. (2024). Retrospective, Non-Interventional, Multicenter Study on the Effectiveness and Safety of Intravesical Bacillus Calmette–Guerin in Patients with Non-Muscle-Invasive Bladder Cancer: Real-World Experience from Six Hospital Centers in Greece. Current Oncology. https://doi.org/10.3390/curroncol32010018
Vancouver
Angelopoulos P, Markopoulos T, Lazarou L, Skolarikos A, Stamatakos P, Papadopoulos GI, et al. Retrospective, Non-Interventional, Multicenter Study on the Effectiveness and Safety of Intravesical Bacillus Calmette–Guerin in Patients with Non-Muscle-Invasive Bladder Cancer: Real-World Experience from Six Hospital Centers in Greece. Current Oncology. 2024. doi:10.3390/curroncol32010018
BibTeX
@article{Angelopoulos2024,
author = {Angelopoulos, Panagiotis and Markopoulos, Titos and Lazarou, Lazaros and Skolarikos, Andreas and Stamatakos, Panagiotis and Papadopoulos, Georgios I and Fragkoulis, Charalampos and Ntoumas, Konstantinos and Moulavasilis, Napoleon and Levis, Panagiotis and Papanikolaou, Dimitrios and Sokolakis, Ioannis and Hatzimouratidis, Konstantinos and Tzanetakos, Charalampos and Psarra, Marina and Mavridoglou, George and Skriapas, Konstantinos and Akrivou, Dimitra and Karagiannis, Dimitrios and Noutsos, Christos and Georgiou, Andreas and Hastazeris, Konstantinos and Gourzoulidis, George and Mitropoulos, Dionysios},
title = {Retrospective, Non-Interventional, Multicenter Study on the Effectiveness and Safety of Intravesical Bacillus Calmette–Guerin in Patients with Non-Muscle-Invasive Bladder Cancer: Real-World Experience from Six Hospital Centers in Greece},
journal = {Current Oncology},
year = {2024},
doi = {10.3390/curroncol32010018}
}
EUVIMED